Bank of New York Mellon Corp Increases Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Bank of New York Mellon Corp raised its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 92.2% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 311,630 shares of the company’s stock after purchasing an additional 149,522 shares during the quarter. Bank of New York Mellon Corp owned 0.53% of Pyxis Oncology worth $1,031,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PYXS. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $40,000. Cetera Advisors LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter worth $100,000. Ikarian Capital LLC purchased a new position in shares of Pyxis Oncology in the first quarter worth $7,082,000. StemPoint Capital LP bought a new position in shares of Pyxis Oncology during the first quarter valued at $7,643,000. Finally, Vanguard Group Inc. boosted its position in shares of Pyxis Oncology by 7.3% during the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after buying an additional 94,740 shares during the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Stock Up 0.3 %

NASDAQ PYXS opened at $3.69 on Friday. The company has a 50-day moving average price of $3.59 and a 200-day moving average price of $3.99. Pyxis Oncology, Inc. has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a market capitalization of $217.30 million, a P/E ratio of -2.71 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, equities research analysts anticipate that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PYXS shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.